Literature DB >> 15596858

Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.

Wataru Akahata1, Zhi-yong Yang, Gary J Nabel.   

Abstract

The immunogenicity of a plasmid DNA expression vector encoding both Gag and envelope (Env), which produced human immunodeficiency virus (HIV) type 1 virus-like particles (VLP), was compared to vectors expressing Gag and Env individually, which presented the same gene products as polypeptides. Vaccination with plasmids that generated VLP showed cellular immunity comparable to that of Gag and cell-mediated or humoral responses similar to those of Env as immunization with separate vectors. These data suggest that DNA vaccines encoding separated HIV polypeptides generate immune responses similar to those generated by viral particles.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15596858      PMCID： PMC538686          DOI： 10.1128/JVI.79.1.626-631.2005

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  25 in total

1.  The stimulation of gene expression by the R region from HTLV-1 and BLV.

Authors:  J Attal; M C Théron; G Kann; P Bolifraud; C Puissant; L M Houdebine
Journal:  J Biotechnol       Date:  2000-02-17       Impact factor: 3.307

2.  Use of overlapping peptide mixtures as antigens for cytokine flow cytometry.

Authors:  H T Maecker; H S Dunn; M A Suni; E Khatamzas; C J Pitcher; T Bunde; N Persaud; W Trigona; T M Fu; E Sinclair; B M Bredt; J M McCune; V C Maino; F Kern; L J Picker
Journal:  J Immunol Methods       Date:  2001-09-01       Impact factor: 2.303

3.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

4.  DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles.

Authors:  W Akahata; E Ido; T Shimada; K Katsuyama; H Yamamoto; H Uesaka; M Ui; T Kuwata; H Takahashi; M Hayami
Journal:  Virology       Date:  2000-09-15       Impact factor: 3.616

5.  Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost.

Authors:  R J Gorelick; R E Benveniste; J D Lifson; J L Yovandich; W R Morton; L Kuller; B M Flynn; B A Fisher; J L Rossio; M Piatak; J W Bess; L E Henderson; L O Arthur
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection.

Authors:  M R Betts; D R Ambrozak; D C Douek; S Bonhoeffer; J M Brenchley; J P Casazza; R A Koup; L J Picker
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Mouse-human heterokaryons support efficient human immunodeficiency virus type 1 assembly.

Authors:  R Mariani; B A Rasala; G Rutter; K Wiegers; S M Brandt; H G Kräusslich; N R Landau
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

8.  Efficient assembly of an HIV-1/MLV Gag-chimeric virus in murine cells.

Authors:  B K Chen; I Rousso; S Shim; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

9.  Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression.

Authors:  Y Huang; W P Kong ; G J Nabel
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

10.  Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.

Authors:  Elena Chertova; Julian W Bess; Bruce J Crise; Raymond C Sowder II; Terra M Schaden; Joanne M Hilburn; James A Hoxie; Raoul E Benveniste; Jeffrey D Lifson; Louis E Henderson; Larry O Arthur
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103
View more
  3 in total

1.  Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag.

Authors:  Kathlyn Santos; Cindy M P Duke; Sol M Rodriguez-Colon; Anthony Dakwar; Shongshan Fan; Michael C Keefer; Howard J Federoff; John G Frelinger; William J Bowers; Stephen Dewhurst
Journal:  Vaccine       Date:  2006-11-15       Impact factor: 3.641

2.  Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.

Authors:  Yasuyuki Eda; Mari Takizawa; Toshio Murakami; Hiroaki Maeda; Kazuhiko Kimachi; Hiroshi Yonemura; Satoshi Koyanagi; Kouichi Shiosaki; Hirofumi Higuchi; Keiichi Makizumi; Toshihiro Nakashima; Kiyoshi Osatomi; Sachio Tokiyoshi; Shuzo Matsushita; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection.

Authors:  Wataru Akahata; Zhi-Yong Yang; Hanne Andersen; Siyang Sun; Heather A Holdaway; Wing-Pui Kong; Mark G Lewis; Stephen Higgs; Michael G Rossmann; Srinivas Rao; Gary J Nabel
Journal:  Nat Med       Date:  2010-01-28       Impact factor: 53.440
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.